Vitamin D Deficiency and Replacement Challenges in Type 1 Gastric Neuroendocrine Tumors: A Comparative Study

Area of Science:

• Endocrinology
• Oncology
• Metabolic Bone Disease

Background:

• Type 1 gastric neuroendocrine tumors (gNET) are linked to autoimmune gastritis and hypergastrinemia.
• Vitamin D deficiency (VDD) is associated with poor outcomes in neuroendocrine tumors (NET), but gNET-specific data are limited.
• Understanding VDD and bone health in gNET is crucial for patient management.

Purpose of the Study:

• To compare vitamin D status, supplementation needs, and bone health in type 1 gNET versus entero-pancreatic NET (EP-NET).
• To identify potential disease-specific factors influencing vitamin D metabolism and bone integrity in gNET.

Main Methods:

• Retrospective analysis of type 1 gNET and age/sex-matched EP-NET cohorts.
• Assessment of VDD prevalence, vitamin D dose requirements for normalization, and bone status (osteoporosis/osteopenia).
• Analysis of dietary habits to control for nutritional confounding factors.

Main Results:

• VDD was significantly more prevalent in gNET (92.3%) than EP-NET (46.2%).
• gNET patients required higher daily cholecalciferol doses and multiple supplementation forms.
• Bone impairment was more common in gNET (61.5%) versus EP-NET (15.4%), independent of diet.

Conclusions:

• Type 1 gNET patients exhibit a greater burden of VDD and bone impairment.
• gNET is associated with increased vitamin D supplementation requirements.
• Findings highlight the need for disease-specific monitoring and management of VDD and bone health in type 1 gNET.